ZBIO•Zenas BioPharma’s third-quarter 2026 net loss more than doubled year over year to $108.9 million. Revenue was $10 million, and cash, cash equivalents and investments totaled $647.1 million at September 30.
Zenas BioPharma reported a third-quarter 2026 net loss of $108.9 million, more than double the year-earlier loss. Revenue rose to $10 million from none a year earlier, attributable to a Bristol Myers Squibb development milestone; research and development expenses increased 70% to $58.5 million, primarily due to higher clinical, regulatory and personnel costs.
The FDA’s target action date for obexelimab in IgG4-related disease is May 27, 2027, and the European marketing application was validated.
